Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life

PHASE4CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

March 12, 2013

Primary Completion Date

February 14, 2019

Study Completion Date

October 3, 2019

Conditions
Otitis MediaFebrile IllnessCoughLower Respiratory Tract InfectionUpper Respiratory Tract Infection
Interventions
BIOLOGICAL

Prevenar13

"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.~Active ingredients~Each 0.5 mL dose contains:~2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg)."

BIOLOGICAL

Synflorix

The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.

Trial Locations (1)

0810

Menzies School of Health Research, Darwin

All Listed Sponsors
collaborator

National Health and Medical Research Council, Australia

OTHER

lead

Menzies School of Health Research

OTHER

NCT01735084 - Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life | Biotech Hunter | Biotech Hunter